Selective activation of the prostaglandin E2 receptor subtype EP2or EP4 leads to inhibition of platelet aggregation

Thrombosis and Haemostasis

Volumn 104, Issue 4, 2010, Pages 796-803

  Kuriyama, Shuhko ^a   Kashiwagi, Hitoshi ^a   Yuhki, Koh Ichi ^a   Kojima, Fumiaki ^a   Yamada, Takehiro ^a   Fujino, Takayuki ^a   Hara, Akiyoshi ^a   Takayama, Koji ^a   Maruyama, Takayuki ^b   Yoshida, Akitoshi ^a   Narumiya, Shuh ^c   Ushikubi, Fumitaka ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b ONO PHARMACEUTICAL CO   (Japan)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Anti platelet agent; EP 4; EP2; Platelet aggregation; Prostaglandin E2

Indexed keywords

(16) (3 METHOXYMETHYL)PHENYL OMEGA TETRANOR- 3,7 DITHIAPROSTAGLANDIN E1; (16) 9 DEOXY 9BETA CHLORO 15 DEOXY 16 HYDROXY 17,17 TRIMETHYLENE 19,20 DIDEHYDROPROSTAGLANDIN E1; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CYCLIC AMP; MESSENGER RNA; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E4 RECEPTOR; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; WILD TYPE;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ANIMALS; BLOOD PLATELETS; CELLS, CULTURED; DINOPROSTONE; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; RECEPTORS, THROMBOXANE;

EID: 77958118151     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-01-0043     Document Type: Article

References (41)

1. 2. Science (Wash DC) 1976; 193: 1135-1137.
2. Needleman P, Kulkarni PS, Raz A. Coronary tone modulation: formation and actions of prostaglandins, endoperoxides, and thromboxanes. Science (Wash DC) 1977; 195: 409-412.
3. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-126.
4. Kobayashi T, Tahara Y, Matsumoto M, et al. Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 2004; 114: 784-794. (Pubitemid 39578737)
5. Schwartz SM, Heimark RL and Majesky MW. Developmental mechanisms underlying pathology of arteries. Physiol Rev 1990; 70: 1177-1209.
6. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (Lond) 1993; 362: 801-809.
7. Eichholtz T, Jalink K, Fahrenfort I, et al. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem J 1993; 291: 677-680. (Pubitemid 23148436)
8. Grainger DJ, Wakefield L, Bethell HW, et al. Release and activation of platelet latent TGF-β in blood clots during dissolution with plasmin. Nat Med 1995; 1: 932-937.
9. Rodriguez C, Gonzalez-Diez M, Badimon L, et al. Sphingosine-1-phosphate: A bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin. Thromb Haemost 2009; 101: 665-673.
10. Coleman RA, Kennedy I, Humphrey PPA, et al. Prostanoids and their receptors, in Comprehensive Medicinal Chemistry Vol 3: Membranes and receptors (Emmett JC ed) 1990. Pergamon Press, Oxford, UK; pp.643-714.
11. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72: 2994-2998.
12. Moncada S, Gryglewski R, Bunting S, et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (Lond) 1976; 263: 663-665.
13. Shio H, Ramwell P. Effect of prostaglandin E 2 and aspirin on the secondary aggregation of human platelets. Nat New Biol 1972; 236: 45-46.
14. McDonald JW, Stuart RK. Interaction of prostaglandins E1 and E2 in regulation of cyclic-AMP and aggregation in human platelets: evidence for a common prostaglandin receptor. J Lab Clin Med 1974; 84: 111-121.
15. Kobzar G, Mardla V, Järving I, et al. Comparison of the inhibitory effect of E-prostaglandins in human and rabbit platelet-rich plasma and washed platelets. Comp Biochem Physiol C 1993; 106: 489-494. (Pubitemid 23342895)
16. 2 analogue, on human blood platelet behaviour and vascular contractility. Eur J Pharmacol 1985; 114: 129-137.
17. Andersen NH, Eggerman TL, Harker LA, et al. On the multiplicity of platelet prostaglandin receptors. I. Evaluation of competitive antagonism by aggregometry. Prostaglandins 1980; 19: 711-735.
18. 2 and hydantoin analogs. Prostaglandins 1984; 27: 683-696.
19. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999; 79: 1193-1226.
20. Sugimoto Y, Negishi M, Hayashi Y, et al. Two isoforms of the EP3 receptor with different carboxyl-terminal domains. Identical ligand binding properties and different coupling properties with Gi proteins. J Biol Chem 1993; 268: 2712-2718. (Pubitemid 23057900)
21. 3 subtype with different C-terminal tail coupling to both stimulation and inhibition of adenylate cyclase. Eur J Biochem 1993; 217: 313-318.
22. 3 prostanoid receptor. FEBS Lett 1994; 338: 170-174.
23. Regan JW, Bailey TJ, Donello JE, et al. Molecular cloning and expression of human EP3 receptors: evidence of three variants with differing carboxyl termini. Br J Pharmacol 1994; 112: 377-385.
24. 3 subtype generated by alternative messenger RNA splicing: multiple second messenger systems and tissue-specific distributions. Mol Pharmacol 1995; 48: 869-879.
25. 3 determines G-protein specificity. Nature (Lond) 1993; 365: 166-170.
26. 2. Eur J Biochem 1995; 228: 23-30.
27. Breyer RM, Bagdassarian CK, Myers SA, et al. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001; 41: 661-690.
28. Kiriyama M, Ushikubi F, Kobayashi T, et al. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 1997; 122: 217-224. (Pubitemid 27397191)
29. Okada Y, Hara A, Ma H, et al. Characterization of prostanoid receptors mediating contraction of the gastric fundus and ileum: studies using mice deficient in prostanoid receptors. Br J Pharmacol 2000; 131: 745-755.
30. Suzawa T, Miyaura C, Inada M, et al. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3, and EP4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology 2000; 141: 1554-1559. (Pubitemid 32269125)
31. 2 in rat supraoptic neurones. J Neuroendocrinol 2002; 14: 64-72.
32. Paul BZ, Ashby B, Sheth SB. Distribution of prostaglandin IP and EP receptor subtypes and isoforms in platelets and human umbilical artery smooth muscle cells. Br J Haematol 1998; 102: 1204-1211. (Pubitemid 28435202)
33. 3. Circulation 2001; 104: 1176-1180.
34. 2 inhibits cAMP production and promotes platelet aggregation. J Clin Invest 2001; 107: 603-610.
35. Narumiya S, FitzGerald GA. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 2001; 108: 25-30. (Pubitemid 32634917)
36. Murata T, Ushikubi F, Matsuoka T, et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature (Lond) 1997; 388: 678-682. (Pubitemid 27366439)
37. Segi E, Sugimoto Y, Yamasaki A, et al. Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. Biochem Biophys Res Commun 1998; 246: 7-12.
38. 3. Nature (Lond) 1998; 395: 281-284.
39. 2. Proc Natl Acad Sci USA 1999; 96: 10501-10506.
40. 2 receptor abnormality: defective signal transduction with normal binding activity. Thromb Haemost 1987; 57: 158-164.
41. 2 potentiates platelet aggregation in human blood. Thromb Haemost 2010; 103: 1268-1269.